[Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].
M A SoldatovL V KlimovA P TolmachevT V KiselevaO V AndrofaginaE M BeketovaS N BelkinaD N BorisovD Yu KarpovM S KrasyukM V KucheryavayaYu D MininaD G NovikovN V RogozhnikovaS V TabakmanYu A TelyatnikK V TretyakovA S FadeevaD S KhanA N ChirkovN A MarskayaN A ShamalovPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
Performing TLT with the drug Revelisa in patients with AI leads to a statistically significant regression of neurological symptoms. A significant proportion of patients achieve a favorable clinical outcome upon discharge from the hospital and in the long term. The obtained data on the efficacy and safety profile correlate with previously published register studies of alteplase in AI.
Keyphrases
- clinical practice
- end stage renal disease
- artificial intelligence
- ejection fraction
- newly diagnosed
- chronic kidney disease
- adverse drug
- prognostic factors
- acute ischemic stroke
- emergency department
- atrial fibrillation
- pulmonary embolism
- big data
- systematic review
- depressive symptoms
- machine learning
- drug induced
- deep learning
- low dose
- brain injury
- data analysis
- cell therapy